JP5593013B2 - Solid-type disinfectant and human body composition - Google Patents

Solid-type disinfectant and human body composition Download PDF

Info

Publication number
JP5593013B2
JP5593013B2 JP2007111614A JP2007111614A JP5593013B2 JP 5593013 B2 JP5593013 B2 JP 5593013B2 JP 2007111614 A JP2007111614 A JP 2007111614A JP 2007111614 A JP2007111614 A JP 2007111614A JP 5593013 B2 JP5593013 B2 JP 5593013B2
Authority
JP
Japan
Prior art keywords
solid
quaternium
type
human body
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007111614A
Other languages
Japanese (ja)
Other versions
JP2008266209A (en
Inventor
伸也 勝倉
正人 清水
正明 速水
Original Assignee
株式会社感光社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社感光社 filed Critical 株式会社感光社
Priority to JP2007111614A priority Critical patent/JP5593013B2/en
Publication of JP2008266209A publication Critical patent/JP2008266209A/en
Application granted granted Critical
Publication of JP5593013B2 publication Critical patent/JP5593013B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)

Description

この発明は、高い殺菌力と広い殺菌スペクトルとを備え、化粧品などに容易に配合できる固体型殺菌剤、及びこの固体型殺菌剤を含む人体施用組成物に関する。   The present invention relates to a solid fungicide that has a high bactericidal power and a wide bactericidal spectrum and can be easily blended in cosmetics, and a human body composition containing the solid fungicide.

化粧品、外用医薬品、外用医薬部外品などの人体施用組成物には、防腐殺菌剤として、一般的にパラベン類、安息香酸及びその塩類、サリチル酸及びその塩類等が使用されている。   Parabens, benzoic acid and its salts, salicylic acid and its salts, etc. are generally used as antiseptic fungicides in compositions applied to the human body such as cosmetics, topical pharmaceuticals, and quasi drugs.

ただ、これらの防腐殺菌剤は皮膚刺激性が高く安全性が低いため、使用配合範囲に制限があるという欠点を有していた。例えば、パラベンや安息香酸塩類の使用制限濃度は1%、安息香酸やサリチル酸の使用制限濃度は0.2%である。また、これらの防腐殺菌剤は、その殺菌効果がpHにより影響され易くて安定化しない、界面活性剤などの他の配合剤と併用すると殺菌力が著しく低下する、などの問題点があった。さらに、これらの防腐殺菌剤を制限範囲内で配合した各種化粧品であっても、その累積使用によって皮膚障害やアレルギー反応が生じることがあり、大きな社会問題にもなっていた。   However, these antiseptic disinfectants have the disadvantage that the range of use is limited because of their high skin irritation and low safety. For example, the use limit concentration of parabens and benzoates is 1%, and the use restriction concentration of benzoic acid and salicylic acid is 0.2%. In addition, these antiseptic disinfectants have problems that their disinfecting effects are easily affected by pH and are not stabilized, and that when used in combination with other compounding agents such as surfactants, the disinfecting power is significantly reduced. Furthermore, even various cosmetics containing these antiseptic disinfectants within the limited range may cause skin disorders and allergic reactions due to their cumulative use, which has become a major social problem.

そこで、消費者の安全性に対する指向に応えるため、化粧品などに防腐殺菌剤を全く配合しないことや、その配合量を極端に低減することが求められるようになっており、現在までにも様々な試みがなされてきた。   Therefore, in order to respond to the consumer's safety orientation, it has been demanded that no antiseptic disinfectant is added to cosmetics or the like, and that the amount of the additive is extremely reduced. Attempts have been made.

具体的には、複数の固体型殺菌剤を使用して、それらの相乗効果を生じさせ、防腐殺菌剤の使用量を軽減する方法が例示できる。また、これら防腐殺菌剤は水相に存在する量により効果が左右されることから、1,3-ブチレングリコール、ジプロピレングリコールなどの多価アルコールを添加して、防腐殺菌剤の水相への分配を高める方法も例示できる。   Specifically, a method of producing a synergistic effect by using a plurality of solid-type disinfectants and reducing the amount of the antiseptic disinfectant used can be exemplified. In addition, since the effect of these antiseptic disinfectants depends on the amount present in the aqueous phase, polyhydric alcohols such as 1,3-butylene glycol and dipropylene glycol are added to the antiseptic disinfectant into the aqueous phase. A method for increasing the distribution can also be exemplified.

ただし、防腐殺菌剤と多価アルコールとの併用により殺菌効果は向上するものの、その効果は多価アルコールを大量に配合しなければ発揮できなかった。例えば、1,3-ブチレングリコール、ジプロピレングリコールは10重量%以上、グリセリンは30重量%以上配合しないと防腐殺菌効果を発揮できない。しかし、これだけの量を配合することは他の成分との兼ね合いを考えると事実上不可能であった。   However, although the bactericidal effect is improved by the combined use of the antiseptic disinfectant and the polyhydric alcohol, the effect cannot be exhibited unless a large amount of the polyhydric alcohol is blended. For example, the antiseptic and sterilizing effect cannot be exhibited unless 1,3-butylene glycol and dipropylene glycol are mixed at 10% by weight or more and glycerin at 30% by weight or more. However, it was practically impossible to add such an amount considering the balance with other ingredients.

ところで、微量でも安定した殺菌効果を示し、皮膚刺激性が低くて安全性が高い物質のとして、クオタニウム73、クオタニウム51、クオタニウム45等のクオタニウム塩、一部のスチリル化合物(例えば、INCI名ジメチルアミノスチリルヘプチルメチルチアゾリュームアイオダイド)が従来から使用されている。   By the way, quaternium salts such as quaternium 73, quaternium 51, and quaternium 45, and some styryl compounds (for example, INCI name dimethylamino) are shown as substances having a stable bactericidal effect even in a small amount and having low skin irritation and high safety. Conventionally, styryl heptylmethyl thiazolium iodide) is used.

なお、クオタニウム73及びスチリル化合物は優れた殺菌剤としてすでに多くの報告があり、これらよりも殺菌作用はやや劣るものの、クオタニウム51は発毛、育毛作用を併せ持つことが報告されており、クオタニウム45は皮膚用として整肌効果のあることが報告されている。   In addition, quaternium 73 and a styryl compound have already been reported as many excellent bactericides, and although the bactericidal action is somewhat inferior to these, it has been reported that quaternium 51 has both hair growth and hair growth action. It has been reported that it has a skin conditioning effect for skin.

また、これらクオタニウム塩等は、少量で効果を示すものの、カチオン性の塩のため水やアルコールに対する溶解性が極めて低いが、他の防腐殺菌剤と異なり微量で効果があるため、エタノール溶液や、1,3-ブチレングリコール、ジプロピレングリコール、グリセリンなどの多価アルコール等の可溶化剤を使用して使用して溶解性の改善が行われている。なお、これらクオタニウム塩は作用効果の面から化粧品で0.002重量%、医薬部外品で0.005重量%配合することを法規上の上限としている。   In addition, although these quaternium salts show an effect in a small amount, the solubility in water and alcohol is extremely low because of the cationic salt, but unlike other antiseptic disinfectants, they are effective in a trace amount, so an ethanol solution, The solubility is improved by using solubilizers such as polyhydric alcohols such as 1,3-butylene glycol, dipropylene glycol and glycerin. These quaternium salts have a legal upper limit of 0.002% by weight for cosmetics and 0.005% by weight for quasi-drugs in terms of action and effect.

さらに、クオタニウム塩等は、幅広い殺菌スペクトルを供えているものの、グラム陽性菌に対する殺菌性に比べ、グラム陰性菌への殺菌性がやや劣っている。そのため、従来はパラベン等の固体型殺菌剤と併用することにより、グラム陰性菌への殺菌性を高めていた。しかし、この場合には、パラベン等の防腐殺菌剤を大幅に減量すること、又は完全に排除することはできなかった(例えば、特許文献1)。   Furthermore, although quaternium salts and the like have a broad bactericidal spectrum, they are slightly inferior in bactericidal properties against gram-negative bacteria compared to bactericidal properties against gram-positive bacteria. Therefore, conventionally, the bactericidal property against Gram-negative bacteria has been enhanced by using it together with a solid-type bactericide such as paraben. However, in this case, the preservative disinfectant such as parabens cannot be greatly reduced or completely eliminated (for example, Patent Document 1).

一方、発明者らは、化粧品原料として一般的に使用されているポリエチレングリコールにクオタニウム塩等を90〜100℃の高温下で一定時間攪拌しながら混合し、これを冷却固化してなる固体型殺菌剤を化粧品等に使用すること、をすでに試みている。   On the other hand, the inventors have mixed solid sterilization obtained by mixing quaternary salt and the like with polyethylene glycol, which is generally used as a cosmetic raw material, with stirring at a high temperature of 90 to 100 ° C. for a certain period of time, and cooling and solidifying the mixture. Attempts have already been made to use the agent in cosmetics.

しかし、この固体型殺菌剤は、混合中は澄明であるものの固化後は暗色化してしまうこと、吸光光度の測定からクオタニウム塩等の多くが分解しており殺菌力が期待できないことから、化粧品等への使用は実用的でなかった。   However, although this solid-type disinfectant is clear during mixing, it becomes dark after solidification, and since many of quaternium salts and the like are decomposed from the measurement of absorptiometry, disinfecting power cannot be expected. Use for was not practical.

特開平11−322591号公報Japanese Patent Laid-Open No. 11-322591

そこで、この発明は、パラベン等の有害な防腐殺菌剤を大幅に減量、又は完全に使用することなく、優れた殺菌性、幅広い殺菌スペクトル、審美性を備え、かつ安全性の高い人体施用組成物を提供すること、及びこの人体施用組成物を容易に調製することができる固体型殺菌剤を提供することを課題とする。   Therefore, the present invention provides a highly safe human body application composition that has excellent bactericidal properties, a wide bactericidal spectrum, and aesthetics without greatly reducing or completely using harmful preservative fungicides such as parabens. It is an object of the present invention to provide a solid-type disinfectant capable of easily preparing this human body application composition.

発明者らは、クオタニウム塩等を加温下でアルコールに溶解したのちに、これと、ポリエチレングリコールとを加温下で混合したのち、冷却固化すれば、クオタニウム塩等と、ポリエチレングリコールとが容易に混合し化学的に安定した固体型殺菌剤を調製できること、及びこの固体型殺菌剤を使用すれば優れた殺菌性と幅広い殺菌スペクトルとを備え、安全性の高い人体施用組成物を容易に調製できることを見出し、この発明を完成させた。   The inventors dissolved the quaternium salt etc. in alcohol under heating, then mixed this with polyethylene glycol under heating, and then cooled and solidified, so that the quaternium salt etc. and polyethylene glycol were easily It is possible to prepare a chemically stable solid-type disinfectant and use this solid-type disinfectant to easily prepare a highly safe human application composition with excellent bactericidal properties and a wide bactericidal spectrum. The present invention was completed by finding out what can be done.

すなわち、請求項1に記載の固体型殺菌剤は、(1)特定のクオタニウム塩、スチリル化合物のうちの少なくとも一種以上を炭素数2〜3のアルコールに加温下で溶解してなる高濃度溶液と、(2)ポリエチレングリコールと、を加温下で混合したのち、冷却固化してなるものである。   That is, the solid-type disinfectant according to claim 1 is (1) a high-concentration solution obtained by dissolving at least one of a specific quaternium salt and a styryl compound in an alcohol having 2 to 3 carbon atoms with heating. (2) Polyethylene glycol is mixed under heating and then solidified by cooling.

また、請求項2に記載の人体施用組成物は、請求項1に記載の固体型殺菌剤を含むものである。なお、人体施用組成物とは、化粧品、医薬部外品、外用医薬部外品など人体の外部に直接施用する組成物を意味する。   Moreover, the human body application composition of Claim 2 contains the solid-type disinfectant of Claim 1. The composition applied to the human body means a composition that is applied directly to the outside of the human body, such as cosmetics, quasi drugs, and external quasi drugs.

この発明の固体型殺菌剤は、微量で殺菌力に優れたクオタニウム塩等と、ポリエチレングリコールとを含むものであり、これを化粧品などの人体施用組成物に含有させることによって、優れた殺菌性、幅広い殺菌スペクトル、審美性を備え、安全性等の高い人体施用組成物を容易に調製することができるようになった。また、この人体施用組成物は、パラベン等の従来からある防腐殺菌剤を含んでいないため、累積使用による皮膚障害やアレルギー反応を引き起こす可能性はほとんどない。そのため、これらの疾病が生じることを理由に化粧等ができなかった人でも、化粧等ができるようになった。   The solid-type disinfectant of the present invention contains a quaternium salt or the like excellent in bactericidal activity in a small amount and polyethylene glycol, and by containing this in a human body application composition such as cosmetics, It has become possible to easily prepare a composition for applying to the human body having a wide sterilization spectrum and aesthetics and high safety. Moreover, since this human body composition does not contain conventional antiseptic fungicides such as parabens, there is almost no possibility of causing skin damage or allergic reaction due to cumulative use. Therefore, even those who could not make up because of the occurrence of these illnesses can now make up.

1.固体型殺菌剤
この発明にかかる固体型殺菌剤は、(1)高濃度溶液と、(2)ポリエチレングリコール(PEG)とを加温下で混合してなるものである。以下にその詳細について説明する。
1. Solid-type disinfectant The solid-type disinfectant according to the present invention is obtained by mixing (1) a high concentration solution and (2) polyethylene glycol (PEG) under heating. The details will be described below.

(1)高濃度溶液
特定のクオタニウム塩及び特定のスチリル化合物のうちの少なくとも一種以上を炭素数2〜3のアルコールに加温下で溶解したものである。
(1) High-concentration solution At least one or more of a specific quaternium salt and a specific styryl compound are dissolved in an alcohol having 2 to 3 carbon atoms with heating.

(i)クオタニウム塩及びスチリル化合物
この発明で使用するクオタニウム塩は、以下のその殺菌性や安全性が確認されている下記のクオタニウム73(化1)、クオタニウム51(化2)及びクオタニウム45(化3)である。また、この発明で使用するスチリル化合物は、INCI名ジメチルアミノスチリルヘプチルメチルチアゾリュームアイオダイド(化4)である。なお、クオタニウム塩及びスチリル化合物は、用途に応じて、その一種を単独で使用してもよく、複数を組み合わせて使用してもよい。

Figure 0005593013
Figure 0005593013
Figure 0005593013
Figure 0005593013
(I) Quaternium salt and styryl compound The quaternium salt used in the present invention has the following quaternium 73 (Chemical Formula 1), quaternium 51 (Chemical Formula 2) and quaternium 45 (Chemical Formula) whose sterilizing properties and safety are confirmed. 3). The styryl compound used in the present invention is the INCI name dimethylaminostyryl heptylmethylthiazolium iodide (Chemical Formula 4). In addition, a quaternium salt and a styryl compound may be used individually by 1 type according to a use, and may be used in combination of multiple.
Figure 0005593013
Figure 0005593013
Figure 0005593013
Figure 0005593013

(ii)炭素数2〜3のアルコール
この発明で使用する炭素数2〜3のアルコールとは、エタノール又はプロパノールのことであり、これらの中でも前記のクオタニウム塩やスチリル化合物の溶解度が高く、安全性、汎用性を備えていることからエタノールが好ましい。なお、これらのアルコールは、用途に応じて、その一種を単独で使用してもよく、複数を組み合わせて使用してもよい。
(Ii) Alcohol having 2 to 3 carbon atoms The alcohol having 2 to 3 carbon atoms used in the present invention is ethanol or propanol, and among these, the solubility of the quaternium salt and the styryl compound is high, and safety. Ethanol is preferred because of its versatility. In addition, according to the use, these alcohols may be used alone or in combination.

(iii)溶解方法
クオタニウム塩、スチリル化合物は加温下で炭素数2〜3のアルコールに溶解する。ここで、加温温度は使用するクオタニウム塩、スチリル化合物及び炭素数2〜3のアルコールによって異なるものの、クオタニウム塩、スチリル化合物の分解を抑制するため75℃以下が好ましく、溶解度を高めるため65℃以上が好ましい。
(Iii) Dissolution method The quaternium salt and styryl compound are dissolved in an alcohol having 2 to 3 carbon atoms under heating. Here, although the heating temperature varies depending on the quaternium salt, styryl compound and alcohol having 2 to 3 carbon atoms to be used, it is preferably 75 ° C. or lower in order to suppress decomposition of the quaternium salt or styryl compound, and 65 ° C. or higher in order to increase the solubility. Is preferred.

また、高濃度溶液中のクオタニウム塩、スチリル化合物の濃度は、後述する人体施用組成物がその効果を生じるように、固体型殺菌剤中の高濃度溶液の含有量、人体施用組成物中の固体型殺菌剤の含有量などを勘案して設定すればよい。ただし、高濃度溶液は希釈して使用するため、なるべく高濃度、できれば飽和濃度に近い濃度であることが好ましい。   In addition, the concentration of the quaternium salt and styryl compound in the high-concentration solution is such that the content of the high-concentration solution in the solid-type disinfectant and the solid in the human-body application composition so that the human-body application composition described later produces its effect. It may be set in consideration of the content of the mold disinfectant. However, since the high-concentration solution is diluted and used, it is preferable that the concentration is as high as possible, preferably close to the saturation concentration.

なお、クオタニウム塩、スチリル化合物は、古くから化粧品、医薬部外品等に殺菌、育毛、ニキビ治療薬など低濃度で幅広い菌種に対して殺菌活性を持つ物質の材料として、多多方面で長年にわたって使用されおり、その安全性は極めて高いことが確認されている。   In addition, quaternium salts and styryl compounds have been used for many years as a material for substances that have bactericidal activity against a wide range of bacterial species at low concentrations such as cosmetics, quasi drugs, etc. It has been confirmed that its safety is extremely high.

そのため、固体型殺菌剤中のクオタニウム塩等の含有量については、その用途に応じて自由に変更することができ特に限定する必要はないが、殺菌効果を考慮すると、0.01重量%〜2.00重量%が好ましく、0.01重量%〜1.00重量%がより好ましい。   Therefore, the content of quaternium salt and the like in the solid-type disinfectant can be freely changed according to its use and is not particularly limited. However, in view of the bactericidal effect, 0.01 wt% to 2.00 wt% Is preferable, and 0.01% by weight to 1.00% by weight is more preferable.

より具体的には、クオタニウム73だけを使用するときには、その含有量が、PEG4,000とPEG6,000との総含有量に対して、0.02〜1.00重量%であることが好ましい。これは、アルコールへの溶解量をなるべく高くするとともに、固体型殺菌剤からクオタニウム塩等を再析出させないためである。   More specifically, when only quaternium 73 is used, its content is preferably 0.02 to 1.00% by weight based on the total content of PEG 4,000 and PEG 6,000. This is because the amount dissolved in the alcohol is made as high as possible and the quaternium salt or the like is not reprecipitated from the solid-type fungicide.

また、クオタニウム51、クオタニウム45、またはジメチルアミノスチリルヘプチルメチルチアゾリュームアイオダイドを組み合わせて使用するときには、その総含有量が、PEG4,000とPEG6,000との総含有量に対して、0.02〜2.00重量%であることが好ましい。これは、クタニウム73に比し、アルコールへの溶解性がよいからである。   Further, when the combination of quaternium 51, quaternium 45, or dimethylaminostyryl heptylmethylthiazolium iodide is used, the total content thereof is 0.02 to 0.02 to the total content of PEG 4,000 and PEG 6,000. It is preferably 2.00% by weight. This is because the solubility in alcohol is better than that of Kutanium 73.

クオタニウム51とクオタニウム73とを組み合わせて使用するときには、その総含有量が、PEG4,000とPEG6,000との総含有量に対して、0.02〜2.00重量%であることが好ましい。これは、単品としての使用量を低減できるからである。   When the quaternium 51 and the quaternium 73 are used in combination, the total content is preferably 0.02 to 2.00% by weight based on the total content of PEG 4,000 and PEG 6,000. This is because the amount used as a single product can be reduced.

クオタニウム45とクオタニウム73とを組み合わせて使用するときには、その総含有量が、PEG4,000とPEG6,000との総含有量に対して、前記と同様の理由から、0.02〜2.00重量%であることが好ましい。   When the quaternium 45 and the quaternium 73 are used in combination, the total content is 0.02 to 2.00% by weight with respect to the total content of PEG 4,000 and PEG 6,000 for the same reason as described above. Is preferred.

クオタニウム51、クオタニウム45、クオタニウム73及びジメチルアミノスチリルヘプチルメチルチアゾリュームアイオダイドを組み合わせて使用するときには、その総含有量が、PEG4,000とPEG6,000との総含有量に対して、0.02〜2.00重量%であることが好ましい。これは、4品混合する場合、単品としての使用量を低減できるからである。   When quaternium 51, quaternium 45, quaternium 73 and dimethylaminostyryl heptylmethyl thiazolium iodide are used in combination, the total content is 0.02 to 4,000 with respect to the total content of PEG 4,000 and PEG 6,000. It is preferably 2.00% by weight. This is because, when four products are mixed, the amount used as a single product can be reduced.

なお、人体施用組成物中のクオタニウム塩、スチリル化合物の含有量については、法律上の理由から、0.002重量%〜0.005重量%が好ましい。   The content of the quaternium salt and styryl compound in the human body application composition is preferably 0.002% by weight to 0.005% by weight for legal reasons.

(2)ポリエチレングリコール
ポリエチレングリコールは、エチレンオキシドのアルカリによりラジカル重合、プロトン開始によるカチオン重合によって合成した水溶性の高分子である。ポリエチレングリコールは含有する高分子の分子量によって、正確には含有する高分子のガウス曲線様の分子量分布によって、PEG6,000、PEG4,000などに分類することができる。例えばPEG6,000の平均分子量は7,300〜9,300であり、PEG4,000の平均分子量は2,700〜3,400である。
(2) Polyethylene glycol Polyethylene glycol is a water-soluble polymer synthesized by radical polymerization with alkali of ethylene oxide and cationic polymerization by proton initiation. Polyethylene glycol can be classified into PEG 6,000, PEG 4,000, etc., depending on the molecular weight of the polymer contained, more precisely, the Gaussian-like molecular weight distribution of the polymer contained. For example, the average molecular weight of PEG 6,000 is 7,300-9,300, and the average molecular weight of PEG 4,000 is 2,700-3,400.

これらのポリエチレングリコールの中でも、PEG6,000、PEG4,000の使用が好ましい。これは、PEG6,000、PEG4,000の溶解点、凝固点が本発明に最も適しているからである。   Among these polyethylene glycols, use of PEG 6,000 or PEG 4,000 is preferable. This is because the melting point and freezing point of PEG 6,000 and PEG 4,000 are most suitable for the present invention.

(3)混合方法
(i)混合方法
前記(1)高濃度溶液と(2)ポリエチレングリコールとを、定法によって加温下で混合したのち冷却固化する。ここで、固体後の形状は錠剤型などの定型を有するものであってもよく、粉末や顆粒状など流動性を有するものであってもよい。
(3) Mixing method (i) Mixing method The above (1) high-concentration solution and (2) polyethylene glycol are mixed under heating by a conventional method and then solidified by cooling. Here, the shape after solid may have a fixed shape such as a tablet shape, or may have fluidity such as powder or granule.

また、混合する際の加温温度は、使用するクオタニウム塩、スチリル化合物及び炭素数2〜3のアルコールによって異なるものの、クオタニウム塩、スチリル化合物の分解を抑制するため75℃以下が好ましく、クオタニウム塩等のポリエチレングリコールへの溶解度を高めて均一に混合するため、70℃℃以上が好ましい。なお、混合したのちに、冷却してなる固化物を粉砕して、40℃程度か40℃前後の温度で真空吸引することにより、高濃度溶液の調製で使用したアルコールを除去してもよい。   Moreover, although the heating temperature at the time of mixing varies depending on the quaternium salt, styryl compound and alcohol having 2 to 3 carbon atoms to be used, it is preferably 75 ° C. or lower in order to suppress decomposition of the quaternium salt and styryl compound, such as quaternium salt In order to increase the solubility of polyethylene glycol in polyethylene glycol and mix uniformly, a temperature of 70 ° C. or higher is preferable. After mixing, the solidified product that has been cooled may be pulverized and vacuum suctioned at a temperature of about 40 ° C. or around 40 ° C. to remove the alcohol used in the preparation of the high-concentration solution.

このようにして調製された固体型殺菌剤は、取り扱いが極めて容易であり、常温で変質、分解することなく安定しており、冷蔵庫中はもちろん、遮光瓶中に入れておけば室温でも保管できる便利な材料である。また、この固体型殺菌剤は、固体であるため、取り扱いや秤量が容易であり、溶解性も高いため、人体施用組成物を調製する際にも容易に配合することができる。   The solid-type disinfectant prepared in this way is extremely easy to handle, stable without deterioration or decomposition at room temperature, and can be stored at room temperature if placed in a light-shielding bottle as well as in a refrigerator. It is a convenient material. Moreover, since this solid-type disinfectant is solid, it is easy to handle and weigh, and has high solubility, so it can be easily blended when preparing a human body application composition.

2.人体施用組成物
この発明の人体施用組成物とは、前記固体型殺菌剤を含むものである。具体的には、前記固体型殺菌剤を公知の有効成分や吸収促進剤とともに、公知の方法によって調製した液剤、ローション剤、クリーム剤、軟膏剤、ゼリー剤、ゲル剤などのことであり、より具体的には洗顔料、化粧水、乳液、クリーム、シャンプー、ヘアトリートメントなどの皮膚用・頭髪用の化粧品、美白、しみやそばかすの予防などの特定の使用目的とした外用医薬部外品、ニキビやアトピー治療用の医薬品などのことである。
2. Human body application composition The human body application composition of the present invention includes the solid-type fungicide. Specifically, liquid solids, lotions, creams, ointments, jellies, gels, etc. prepared by known methods together with known active ingredients and absorption promoters, and more Specifically, cosmetics for skin and hair such as facial cleansers, lotions, emulsions, creams, shampoos, hair treatments, quasi-drugs for external use for specific purposes such as whitening, spots and freckles prevention, and acne And pharmaceuticals for the treatment of atopy.

以下に、この発明の固体型殺菌剤、人体施用組成物を実施例として具体的に調製し、その特性を試験した。なお、この発明は、いかなる意味においても以下の実施例に限定されるものではない。   Below, the solid-type disinfectant and human body composition of this invention were specifically prepared as examples, and the characteristics were tested. In addition, this invention is not limited to a following example in any meaning.

(1)経時安定性試験
(i)検量線の作成
クオタニウム73 5mgを精秤し、エタノール200mlに70℃で加温しながら溶解して溶液を調製し、この溶液10mlを精製水100mlに希釈した。つぎに、この溶液を順次段階希釈した希釈溶液列を調製した。さらに、この希釈溶液列のAbs.Max 411±2nmを分光光度計で測定し、検量線を作成した。
(1) Stability test over time (i) Preparation of calibration curve Quotanium 73 5 mg was precisely weighed and dissolved in 200 ml of ethanol while heating at 70 ° C. to prepare a solution, and 10 ml of this solution was diluted in 100 ml of purified water. . Next, a diluted solution train was prepared by serially diluting this solution. Further, Abs. Max 411 ± 2 nm of this diluted solution row was measured with a spectrophotometer to prepare a calibration curve.

また、同様にして、クオタニウム51、クオタニウム45、ジメチルアミノスチリルヘプチルメチルチアゾリュウムイオダイドについても検量線を作成した。なお、クオタニウム51のAbs.Maxは404±2nm、クオタニウム45のAbs.Maxは363±2nm、ジメチルアミノスチリルヘプチルメチルチアゾリュウムイオダイドのAbs.Maxは480±2nmであるとして測定し、検量線を作成した。   Similarly, calibration curves were prepared for quaternium 51, quaternium 45, and dimethylaminostyryl heptylmethylthiazolium iodide. Note that the Abs.Max of quaternium 51 is 404 ± 2 nm, the Abs.Max of quaternium 45 is 363 ± 2 nm, and the Abs.Max of dimethylaminostyryl heptylmethylthiazolium iodide is 480 ± 2 nm. It was created.

(ii)固体型殺菌剤の調製
クオタニウム塩等、アルコール、ポリエチレングリコールを含む固体型殺菌剤を調製した。具体的には、例えば、クオタニウム73 0.2gをイソプロパノール5.0mlに70〜75℃の加温下で溶解して高濃度溶液とし、この高濃度溶液を70℃の加温下でポリエチレングリコールと混合したのち、常温で冷却固化することによって調製した。なお、固体型殺菌剤の剤型は、定型(錠剤型、型ワク枠型)、粉末、顆粒状のものを調製した。また、「PEG4,000」はpH6.8(5%Aq)、凝固点56℃、平均分子量3360のもの、「PEG6,000」はpH6.8(5%Aq)、凝固点60℃、平均分子量8360のものを使用した。
(Ii) Preparation of solid-type disinfectant A solid-type disinfectant containing alcohol and polyethylene glycol such as quaternium salt was prepared. Specifically, for example, 0.2 g of quaternium 73 was dissolved in 5.0 ml of isopropanol under heating at 70 to 75 ° C. to obtain a high concentration solution, and this high concentration solution was mixed with polyethylene glycol under heating at 70 ° C. Then, it prepared by cooling and solidifying at normal temperature. In addition, the solid-type disinfectant was prepared in a fixed form (tablet form, mold frame form), powder, and granular form. In addition, “PEG 4,000” has a pH of 6.8 (5% Aq), a freezing point of 56 ° C. and an average molecular weight of 3360, and “PEG 6,000” has a pH of 6.8 (5% Aq), a freezing point of 60 ° C. and an average molecular weight of 8360. I used something.

なお、このようにして作成した固体型殺菌剤中のクオタニウム塩等の濃度が、分光光度計と前記検量線によって測定できることを、安定試験を開始する前に確認した。例えば、クオタニウム73を0.02重量%含む固体型殺菌剤の粉末1gをメスフラスコ中に入れ、50mlのエタノールを加えて、精製水で100mlにメスアップして溶解した。この溶解液を、測定範囲に収まるように精製水で段階的に希釈した。これらの希釈液のAbs.Max 411±2nmにおける吸光度を分光光度計で測定し、検量線から含有量を算出した。その結果、クオタニウム73の濃度が0.02%±0.001重量%の範囲内にあることが分かった。この結果及び他の固体型殺菌剤における同様の結果から、前記検量線を使用することにより、クオタニウム塩等の濃度を正確に測定できることを確認した。   In addition, it confirmed before starting a stability test that the density | concentrations, such as a quaternium salt, in the solid type fungicide produced in this way can be measured with a spectrophotometer and the said calibration curve. For example, 1 g of a solid-type fungicide powder containing 0.02% by weight of quaternium 73 was placed in a volumetric flask, 50 ml of ethanol was added, and the volume was made up to 100 ml with purified water and dissolved. This dissolved solution was diluted stepwise with purified water so as to be within the measurement range. Absorbance of these diluted solutions at Abs. Max 411 ± 2 nm was measured with a spectrophotometer, and the content was calculated from a calibration curve. As a result, it was found that the concentration of quaternium 73 was in the range of 0.02% ± 0.001% by weight. From this result and similar results in other solid-type fungicides, it was confirmed that the concentration of quaternium salt and the like can be accurately measured by using the calibration curve.

(iii)経時安定性の測定
このようにして調製した固体型殺菌剤中のクオタニウム塩濃度を、調製時、半月、1ヶ月、3ヶ月、6ヶ月の室内に常温で保管したものと、冷蔵庫内の冷暗所に保管したものに分けて安定性試験を行った。また、温度37℃、湿度60%、壁面に2灯の20wの蛍光灯を取り付けた恒温庫に各固体型殺菌剤を保管し、調製時、1ヶ月、3ヶ月、6ヶ月にクオタニウム塩の濃度を測定する強制的経時安定試験も行った。
(iii) Measurement of stability over time The concentration of quaternium salt in the solid fungicide prepared in this way was stored at room temperature in the room for half a month, 1 month, 3 months, 6 months at the time of preparation, The stability test was performed separately for those stored in a cool and dark place. In addition, each solid-type disinfectant is stored in a constant temperature chamber with a temperature of 37 ° C, humidity of 60%, and two 20w fluorescent lamps mounted on the wall, and the concentration of quaternium salt is 1 month, 3 months, and 6 months at the time of preparation. A forced aging stability test was also conducted.

その結果、クオタニウム45だけを含有する固体型殺菌剤について、強制的経時安定試験を行った場合に、6ヶ月後にその濃度が試験開始時の99.70±0.20に減少したことを除いて、吸光度の減衰、変質による吸光度曲線の変化は一切認められず、固体型殺菌剤が長期間安定していることを確認した。   As a result, when solid sterilizer containing only quaternium 45 was subjected to a forced aging stability test, the absorbance decreased except that the concentration decreased to 99.70 ± 0.20 at the start of the test after 6 months. No change in absorbance curve due to alteration was observed, confirming that the solid fungicide was stable for a long time.

(2)刺激性試験
(i)固体型殺菌剤の調製
下記の表1に示す配合割合(表中の値はW/W%)で、クオタニウム塩、アルコール、ポリエチレングリコールを含む固体型殺菌剤を調製した。具体的には、クオタニウム塩をアルコールに70〜75℃の加温下で溶解して高濃度溶液とし、この高濃度溶液を75℃の加温下でポリエチレングリコールと混合したのち、常温で冷却固化することによって各実施例を調製した。
(2) Irritation test
(i) Preparation of Solid Type Bactericide A solid type bactericide containing a quaternium salt, alcohol, and polyethylene glycol was prepared at the blending ratio shown in Table 1 below (value in the table is W / W%). Specifically, a quaternium salt is dissolved in alcohol at a temperature of 70 to 75 ° C. to make a high concentration solution, and this high concentration solution is mixed with polyethylene glycol under a temperature of 75 ° C. and then cooled and solidified at room temperature. Each example was prepared by:

Figure 0005593013
Figure 0005593013

(ii)刺激性試験
実施例1から実施例3の固体型殺菌剤に対してそれぞれ5匹ずつ、計15匹のモルモットを使用して行った。具体的には、実施例1から実施例3の固体型殺菌剤を生理食塩水で10倍に希釈し、この希釈液をモルモットの背部に塗って皮膚の炎症を調べた。その結果、いずれの固体型殺菌剤についても皮膚に対する刺激は殆どなかった。
(Ii) Irritation test The test was carried out using 15 guinea pigs, 5 for each of the solid-type fungicides of Examples 1 to 3. Specifically, the solid fungicides of Examples 1 to 3 were diluted 10-fold with physiological saline, and this diluted solution was applied to the back of a guinea pig to examine skin inflammation. As a result, there was almost no irritation | stimulation with respect to skin about any solid-type disinfectant.

(3)殺菌性試験
複数の固体型殺菌剤を調製し、その最小発育阻止濃度(MIC)を測定することにより、その殺菌力を試験した。
(3) Bactericidal test A plurality of solid-type bactericides were prepared, and their bactericidal activity was tested by measuring their minimum inhibitory concentration (MIC).

(i)固体型殺菌剤の調製
下記の表2に示す配合割合(表中の値はW/W%)で、クオタニウム塩等、アルコール、ポリエチレングリコールを含む固体型殺菌剤を調製した。具体的には、クオタニウム塩をアルコールに70℃の加温下で溶解して高濃度溶液とし、この高濃度溶液を70〜75℃の加温下でポリエチレングリコールと混合したのち、常温で冷却固化することによって各実施例を調製した。
(i) Preparation of Solid Type Bactericide A solid type bactericide containing alcohol, polyethylene glycol, etc., such as a quaternium salt, was prepared at the blending ratio shown in Table 2 below (value in the table is W / W%). Specifically, a quaternium salt is dissolved in alcohol at a temperature of 70 ° C. to make a high concentration solution, and this high concentration solution is mixed with polyethylene glycol at a temperature of 70 to 75 ° C., and then cooled and solidified at room temperature. Each example was prepared by:

Figure 0005593013
Figure 0005593013

(ii)MICの測定
まず、前記6種の固体型殺菌剤それぞれについて、生理食塩水で希釈してクオタニウム塩の濃度が0.02%の水溶液(規定溶液)を調製した。そして、各規定溶液を生理食塩水で段階的にさらに希釈して段階希釈系列(クオタニウム塩の濃度が0.02〜0.0005%)を作成した。また、供試菌をブイヨン培地で約18時間2回前培養した培養液を濁度計で測定して108cells/mlと仮定し、SCD培地で約105cells/mlに希釈したものを菌懸濁液として準備した。なお、供試菌としてはEscherichia coli IFO3972(大腸菌)及びStaphylococcus aureus IFO13276(黄色ブドウ状球菌)を使用した。また、菌数はコロニーカウント法により確認した。
(ii) Measurement of MIC First, each of the six types of solid-type fungicides was diluted with physiological saline to prepare an aqueous solution (normal solution) having a quaternium salt concentration of 0.02%. Each defined solution was further diluted stepwise with physiological saline to prepare a serial dilution series (quantum salt concentration of 0.02 to 0.0005%). In addition, the culture solution in which the test bacteria were pre-cultured twice in bouillon medium for about 18 hours was measured with a turbidimeter and assumed to be 10 8 cells / ml, and diluted with SCD medium to about 10 5 cells / ml. Prepared as a fungal suspension. In addition, Escherichia coli IFO3972 (Escherichia coli) and Staphylococcus aureus IFO13276 (Staphylococcus aureus) were used as test bacteria. The number of bacteria was confirmed by the colony count method.

つぎに、乾熱滅菌済みの15ml容試験管に、各種濃度に調整した希釈液とSCD培地をそれぞれ1.4mlずつ入れ、103cells/mlとなるように菌懸濁液70μlを接種し、35℃で24時間培養を行った。培養完了後、菌の増殖を目視にて判断したのち、完全に菌の増殖が阻止された濃度のものを1g採取し、寒天培地中24時間培養して完全阻止を確認してMICとした。その結果を表3に示す。 Next, in a 15 ml test tube that has been sterilized by dry heat, put 1.4 ml each of the diluted solution and SCD medium adjusted to various concentrations, inoculate 70 μl of the bacterial suspension to 10 3 cells / ml, 35 Culturing was carried out at 24 ° C. for 24 hours. After the completion of the culture, the growth of the bacteria was judged visually, and 1 g of a sample having a concentration at which the growth of the bacteria was completely inhibited was collected and cultured in an agar medium for 24 hours to confirm complete inhibition, thereby obtaining a MIC. The results are shown in Table 3.

Figure 0005593013
Figure 0005593013

表3の結果から、クオタニウム73を含む実施例4は0.0005〜0.005%で、クオタニウム51を含む実施例5は0.001〜0.01%で、クオタニウム45を含む実施例6は0.005〜0.015%で、スチリル化合物(化4)を含む実施例7は0.00025〜0.0025%でS.aureus及びE.coliの増殖を抑制できることが分かった。また、各固体型殺菌剤のMICは、各固体型殺菌剤が含むクオタニウム塩等のMIC値とほぼ同等の値を示していることも分かった。さらに、比較的殺菌活性の弱いクオタニウム51や45にクオタニウム73やスチリル化合物(化4)を混合した固体型殺菌剤(実施例8、実施例9)でも、充分高い殺菌活性が得られた。   From the results of Table 3, Example 4 containing quaternium 73 is 0.0005 to 0.005%, Example 5 containing quaternium 51 is 0.001 to 0.01%, and Example 6 containing quaternium 45 is 0.005 to 0.015%, which is a styryl compound. Example 7 containing (Chemical Formula 4) was found to be able to suppress the growth of S. aureus and E. coli at 0.00025-0.0025%. It was also found that the MIC of each solid fungicide showed a value almost equal to the MIC value of quaternium salt etc. contained in each solid fungicide. Furthermore, sufficiently high bactericidal activity was also obtained with solid type bactericides (Examples 8 and 9) in which quaternium 51 and 45 having relatively weak bactericidal activity were mixed with quaternium 73 and a styryl compound (Chemical Formula 4).

これらの結果から、各固体型殺菌剤は高い殺菌性を備えているとともに、固体型殺菌剤に調製しても含有するクオタニウム塩等の殺菌力は低下しないことが確認できた。また、複数のクオタニウム塩等を混合することによって、殺菌力を向上させることができるので、複数のクオタニウム塩を含む人体施用組成物を製造する場合には、クオタニウム塩等を人体施用組成物にそれぞれ個別に配合するのではなく、複数のクオタニウム塩を含む固体型殺菌剤を調製し、調製した固体型殺菌剤を配合したほうが簡便であることが確認できた。   From these results, it was confirmed that each solid-type fungicide has high bactericidal properties and that the bactericidal power of quaternium salts and the like contained therein does not decrease even when prepared in a solid-type fungicide. Moreover, since a bactericidal power can be improved by mixing a plurality of quaternium salts, etc., when producing a human body application composition containing a plurality of quaternium salts, each of the quaternium salts and the like is added to the human body composition. It was confirmed that it was easier to prepare a solid-type disinfectant containing a plurality of quaternium salts, and to blend the prepared solid-type disinfectant, instead of individually mixing.

(4)溶解性試験
クオタニウム塩の溶解方法を変えて固体型殺菌剤を調製したのち、固体型殺菌剤に含まれるクオタニウム塩の濃度を測定することにより、溶解方法の違いが固体型殺菌剤中のクオタニウム塩の濃度に与える影響を調べた。
(4) Solubility test After changing the dissolution method of quaternium salt to prepare solid-type disinfectant, the concentration of quaternium salt contained in the solid-type disinfectant is measured. The effect of quaternium salt on the concentration was investigated.

(i)クオタニウム73
まず、クオタニウム73、0.01gをエタノール5gに70℃の加温下で溶解したのち、これをPEG 6,000、94.99gに70〜75℃の加温下で混合して、この発明の固体型殺菌剤を調製した。また、クオタニウム73、0.01gをPEG 6,000、99.99gに90〜95℃の加温下で強制的に加熱混合して、比較対照となる固体型殺菌剤を調製した。
(I) Quotanium 73
First, 0.01 g of quaternium 73, dissolved in 5 g of ethanol under heating at 70 ° C., and then mixed with PEG 6,000, 94.99 g under heating at 70-75 ° C. Was prepared. Also, quaternium 73, 0.01 g was forcibly heated and mixed with PEG 6,000, 99.99 g under heating at 90-95 ° C. to prepare a solid-type fungicide as a comparative control.

つぎに、調製した固体型殺菌剤1.0gをエタノール100mlに溶解し、希釈液の吸光度を、測定波長を変えながら測定した。その結果を図1に示す。なお、(a)はこの発明の固体型殺菌剤の吸光度を測定した結果であり、(b)は比較対照となる固体型殺菌剤の吸光度を測定した結果である。   Next, 1.0 g of the prepared solid fungicide was dissolved in 100 ml of ethanol, and the absorbance of the diluted solution was measured while changing the measurement wavelength. The result is shown in FIG. In addition, (a) is the result of measuring the absorbance of the solid fungicide of the present invention, and (b) is the result of measuring the absorbance of the solid fungicide as a comparative control.

図1から、吸収極大波長である411nm付近の吸光度を(a)と(b)の間で比較すると、(a)に比して(b)は明らかに濃度の低減が認められた。この結果から、この発明の固体型殺菌剤は、比較対照となる固体型殺菌剤と比較して、クオタニウム塩が分解していないことが確認できた。なお、(a)の溶液が淡黄色であるのに対して、(b)は暗褐黄色であり、審美性の点においても、この発明の固体型殺菌剤の方が優れていることが確認できた。   From FIG. 1, when the absorbance near 411 nm, which is the maximum absorption wavelength, was compared between (a) and (b), a decrease in concentration was clearly observed in (b) compared to (a). From this result, it was confirmed that the solid-type disinfectant of the present invention was not decomposed compared to the solid-type disinfectant as a comparative control. The solution of (a) is light yellow, whereas (b) is dark brown yellow, and it is confirmed that the solid fungicide of this invention is superior also in terms of aesthetics. did it.

クオタニウム51を使用して、同様の方法により溶解方法の違いが固体型殺菌剤中のクオタニウム塩の濃度に与える影響を調べた。   Using quaternium 51, the effect of the difference in dissolution method on the concentration of quaternium salt in the solid-type fungicide was examined by the same method.

(ii)クオタニウム51
まず、クオタニウム51、0.01gをエタノール5gに70℃の加温下で溶解したのち、これをPEG 6,000、94.99gに70〜75℃の加温下で混合して、この発明の固体型殺菌剤を調製した。また、クオタニウム51、0.01gをPEG 6,000、 99.99gに90〜95℃の加温下で強制的に加熱混合して、比較対照となる固体型殺菌剤を調製した。
(Ii) Quaternium 51
First, 51 g of quaternium, 0.01 g, was dissolved in 5 g of ethanol under heating at 70 ° C., and then mixed with PEG 6,000, 94.99 g under heating at 70 to 75 ° C. Was prepared. Also, quaternium 51, 0.01 g was forcibly heated and mixed with PEG 6,000, 99.99 g at 90-95 ° C. to prepare a solid-type fungicide as a comparative control.

つぎに、調製した固体型殺菌剤1.0gをエタノール100mlに溶解し、希釈液の吸光度を測定波長を変えながら測定した。その結果を図2に示す。なお、(a)はこの発明の固体型殺菌剤の吸光度を測定した結果であり、(b)は比較対照となる固体型殺菌剤の吸光度を測定した結果である。   Next, 1.0 g of the prepared solid fungicide was dissolved in 100 ml of ethanol, and the absorbance of the diluted solution was measured while changing the measurement wavelength. The result is shown in FIG. In addition, (a) is the result of measuring the absorbance of the solid fungicide of the present invention, and (b) is the result of measuring the absorbance of the solid fungicide as a comparative control.

図2から、吸収極大波長である404nm付近の吸光度を(a)と(b)の間で比較すると、有意な差異が認められた。すなわち、この発明の固体型殺菌剤と比較対照となる固体型殺菌剤では、そのオタニウム51の濃度が有意の差異があることが分かった。この結果から、この発明の固体型殺菌剤は、比較対照となる固体型殺菌剤と比較して、クオタニウム塩が分解していないことが確認できた。なお、(a)の溶液が淡黄色であるのに対して、(b)は暗褐黄色であり、審美性の点においても、この発明の固体型殺菌剤の方が優れていることが確認できた。   From FIG. 2, a significant difference was recognized when the absorbance at around 404 nm, which is the maximum absorption wavelength, was compared between (a) and (b). In other words, it was found that the solid-type fungicide used as a comparison control with the solid-type fungicide of the present invention had a significant difference in the concentration of onium 51. From this result, it was confirmed that the solid-type disinfectant of the present invention was not decomposed compared to the solid-type disinfectant as a comparative control. The solution of (a) is light yellow, whereas (b) is dark brown yellow, and it is confirmed that the solid fungicide of this invention is superior also in terms of aesthetics. did it.

(5)使用感等の試験
(i)人体施用組成物の調製
人体施用組成物を以下の表4〜表9に記載の処方に従って、定法により調製した。
(5) Test of feeling of use etc. (i) Preparation of human body application composition The human body application composition was prepared by the usual method according to prescription of the following Tables 4-9.

Figure 0005593013
Figure 0005593013

Figure 0005593013
Figure 0005593013

Figure 0005593013
Figure 0005593013

Figure 0005593013
Figure 0005593013

Figure 0005593013
Figure 0005593013

Figure 0005593013
Figure 0005593013

(ii)使用感等の試験
調製したヘアトニック(表5に記載)は、男女それぞれ5人ずつに10名に1日1回3週間に渡って、頭部に振り掛けて、その後すぐにマッサージすることによって使用してもらい、その使用感、清涼感、刺激性の有無、かゆみの発生について感応評価をしてもらった。また、O/W型クリーム(表7に記載)は、女性10名に1日1回2週間に渡って、顔面に塗布して、すり込む形で試用してもらい、使用感、しっとり感、かゆみ、刺激の発生などについて感応評価をしてもらった。
(Ii) Usability test etc. The prepared hair tonic (listed in Table 5) is sprinkled on the head once a day for 3 weeks for 5 males and 5 females, and then immediately massaged. I was asked to evaluate the use feeling, cool feeling, presence or absence of irritation, and the occurrence of itching. In addition, O / W type cream (listed in Table 7) was applied to the face of 10 women once a day for 2 weeks and tried in the form of rubbing, feeling of use, moist feeling, itching I was asked to evaluate the sensitivity of the stimulus.

その結果、何れの被験者にも使用による赤みや炎症の発生等の問題が生じることはなく、使用感も良好であるとの回答をえた。また、刺激性については、大部分の人からは刺激をあまり感じないとの回答をえた。ただ、O/W型クリームを使用した被験者のうちの一人から口まわり、顎下部分で、極めて低いが刺激を感じるとの回答があった。以上の結果から、前記のヘアトニック及びO/W型クリームは使用感に優れ、刺激性も低いことが確認できた。   As a result, it was answered that none of the subjects suffered from problems such as redness or inflammation due to use, and the feeling of use was good. As for irritation, most people answered that they did not feel much irritation. However, one of the subjects who used the O / W type cream responded that they felt irritation in the mouth and submandibular region, although it was extremely low. From the above results, it was confirmed that the hair tonic and O / W type cream were excellent in use feeling and low in irritation.

溶解方法の違いが、固体型殺菌剤に含まれるクオタニウム73の分解に与える影響を示す図である。なお、(a)はこの発明の固体型殺菌剤の吸光度を測定した結果であり、(b)は比較対照となる固体型殺菌剤の吸光度を測定した結果である。It is a figure which shows the influence which the difference in a melt | dissolution method has on decomposition | disassembly of quaternium 73 contained in a solid-type disinfectant. In addition, (a) is the result of measuring the absorbance of the solid fungicide of the present invention, and (b) is the result of measuring the absorbance of the solid fungicide as a comparative control. 溶解方法の違いが、固体型殺菌剤に含まれるクオタニウム51の分解に与える影響を示す図である。なお、(a)はこの発明の固体型殺菌剤の吸光度を測定した結果であり、(b)は比較対照となる固体型殺菌剤の吸光度を測定した結果である。It is a figure which shows the influence which the difference in a melt | dissolution method has on decomposition | disassembly of the quaternium 51 contained in a solid-type disinfectant. In addition, (a) is the result of measuring the absorbance of the solid fungicide of the present invention, and (b) is the result of measuring the absorbance of the solid fungicide as a comparative control.

Claims (2)

(1)次式1(化1)で示されるクオタニウム73、次式2(化2)で示されるクオタニウム51、次式3(化3)で示されるクオタニウム45及び次式4(化4)で示されるスチリル化合物からなる群れより選ばれた少なくとも一種の殺菌剤0.001〜2.00重量部を、炭素数2〜3のアルコール5〜10重量部に、65〜75℃の加温下で溶解してなる高濃度溶液と、
(2)平均分子量が2,700〜9,300のポリエチレングリコール88〜94.999重量部と、
70〜75℃の加温下で混合したのち、冷却固化してなる固体型殺菌剤。
Figure 0005593013
Figure 0005593013
Figure 0005593013
Figure 0005593013
(1) Quotanium 73 represented by the following formula 1 (Chemical formula 1), quaternium 51 represented by the following formula 2 (Chemical formula 2), quaternium 45 represented by the following formula 3 (Chemical formula 3), and Formula 4 (Chemical formula 4) 0.001 to 2.00 parts by weight of at least one fungicide selected from the group consisting of the styryl compounds shown is dissolved in 5 to 10 parts by weight of alcohol having 2 to 3 carbon atoms under heating at 65 to 75 ° C. A highly concentrated solution;
(2) 88 to 94.999 parts by weight of polyethylene glycol having an average molecular weight of 2,700 to 9,300 ,
Is a solid-type disinfectant obtained by mixing at 70 to 75 ° C. and then solidifying by cooling.
Figure 0005593013
Figure 0005593013
Figure 0005593013
Figure 0005593013
請求項1に記載の固体型殺菌剤を含有する人体施用組成物。         A human body composition containing the solid fungicide according to claim 1.
JP2007111614A 2007-04-20 2007-04-20 Solid-type disinfectant and human body composition Expired - Fee Related JP5593013B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007111614A JP5593013B2 (en) 2007-04-20 2007-04-20 Solid-type disinfectant and human body composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007111614A JP5593013B2 (en) 2007-04-20 2007-04-20 Solid-type disinfectant and human body composition

Publications (2)

Publication Number Publication Date
JP2008266209A JP2008266209A (en) 2008-11-06
JP5593013B2 true JP5593013B2 (en) 2014-09-17

Family

ID=40046217

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007111614A Expired - Fee Related JP5593013B2 (en) 2007-04-20 2007-04-20 Solid-type disinfectant and human body composition

Country Status (1)

Country Link
JP (1) JP5593013B2 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6143102A (en) * 1984-08-03 1986-03-01 Kao Corp Cosmetic
JPH08119849A (en) * 1994-10-20 1996-05-14 Kose Corp Skin preparation for external use
JP4815085B2 (en) * 1999-11-12 2011-11-16 アボット・ラボラトリーズ Solid dispersion pharmaceutical formulation
US6919378B2 (en) * 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
JP2005089355A (en) * 2003-09-17 2005-04-07 Ichimaru Pharcos Co Ltd Isomaltooligosaccharide-containing ameliorant for indigenous skin bacterial flora
JP2006182731A (en) * 2004-12-28 2006-07-13 Ichimaru Pharcos Co Ltd Cosmetic composition or food and drink
JP2007008909A (en) * 2005-07-04 2007-01-18 Advance Co Ltd Cosmetic having antibacterial selectivity
JP4429262B2 (en) * 2005-12-09 2010-03-10 壽製薬株式会社 Fenofibrate solid dispersion

Also Published As

Publication number Publication date
JP2008266209A (en) 2008-11-06

Similar Documents

Publication Publication Date Title
JP6207541B2 (en) Oral composition
JP5062708B2 (en) Antiseptic disinfectant and human body composition
KR102161832B1 (en) Zinc amino acid complex with cysteine
EP0835655B1 (en) Antibacterial/bactericidal/antiseptic agent, dermatologic preparation, and detergent composition
WO2016002767A1 (en) Composition for external application
EP2404502B1 (en) Compositions containing pyrrolidone carboxylic acid (pca) and metallic salts
EP2510916A1 (en) Antiseptic pharmaceutical composition for oral hygiene and the treatment of oral diseases of microbial origin
JP2011074082A (en) Antiseptic sterilizer and composition for application to human body
ES2270314T3 (en) COSMETIC USE OF FITANTRIOL AS AN AGENT TO AVOID OR REDUCE THE ADHESION OF MICROORGANISMS TO THE SURFACE OF THE SKIN AND / OR THE MUCOSES.
JP5210527B2 (en) Antiseptic sterilizing moisturizer and composition for external application on skin and hair
KR102272901B1 (en) Composition for external application to the skin containing meso-2,3-butanediol as a preservative
JP4091559B2 (en) Antiseptic disinfectant and cosmetics, pharmaceuticals and foods containing the antiseptic disinfectant
JP4734293B2 (en) Antiseptic disinfectant and human body composition
JP2016027033A (en) Composition for external application, ophthalmic composition, antibacterial agent, and antibacterial method
JP3774219B2 (en) Antiseptic disinfectant and cosmetics, pharmaceuticals and foods containing the antiseptic disinfectant
JP4294505B2 (en) Antiseptic disinfectant and cosmetics, pharmaceuticals and foods containing the antiseptic disinfectant
JP2005068095A (en) Antiseptic fungicide and cosmetic, medicine and food compounded with antiseptic fungicide
JP4999321B2 (en) Drugs containing antiseptic disinfectant and antiseptic disinfection method
JP5593013B2 (en) Solid-type disinfectant and human body composition
JP2017088510A (en) Composition having azulene compound, and agent and method for preventing discoloration of azulene compound
KR20120112538A (en) Emulsion-type liquid composition for oral cavity, and process for production thereof
JP4149335B2 (en) Oral liquid composition and method for producing the same
WO2016159184A1 (en) Topical composition for amelioration of acne vulgaris
JP4315831B2 (en) Antiseptic disinfectant and cosmetics, pharmaceuticals and foods containing the antiseptic disinfectant
JP2005232012A (en) Antiseptic sterilizer, and cosmetic, medicine and food compounded with the antiseptic sterilizer

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091015

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110802

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120905

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20121106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140804

R150 Certificate of patent or registration of utility model

Ref document number: 5593013

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees